S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
Log in
NASDAQ:MRTX

Mirati Therapeutics News Headlines

$159.49
-4.30 (-2.63 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$159.25
Now: $159.49
$168.63
50-Day Range
$124.06
MA: $141.71
$162.56
52-Week Range
$66.01
Now: $159.49
$171.48
Volume467,362 shs
Average Volume514,701 shs
Market Capitalization$7.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8

Headlines

Mirati Therapeutics (NASDAQ MRTX) News Headlines Today

Source:
DateHeadline
Oppenheimer Boosts Mirati Therapeutics (NASDAQ:MRTX) Price Target to $190.00Oppenheimer Boosts Mirati Therapeutics (NASDAQ:MRTX) Price Target to $190.00
marketbeat.com - September 21 at 7:42 AM
Piper Sandler Increases Mirati Therapeutics (NASDAQ:MRTX) Price Target to $170.00Piper Sandler Increases Mirati Therapeutics (NASDAQ:MRTX) Price Target to $170.00
americanbankingnews.com - September 21 at 8:39 AM
Mirati Therapeutics (NASDAQ:MRTX) PT Raised to $190.00Mirati Therapeutics (NASDAQ:MRTX) PT Raised to $190.00
americanbankingnews.com - September 21 at 8:01 AM
Mirati sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancerMirati' sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
seekingalpha.com - September 18 at 1:14 PM
Mirati Therapeutics (NASDAQ:MRTX) Rating Lowered to Neutral at CitigroupMirati Therapeutics (NASDAQ:MRTX) Rating Lowered to Neutral at Citigroup
americanbankingnews.com - September 18 at 8:27 AM
Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual CongressMirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress
finance.yahoo.com - September 18 at 8:13 AM
Mirati Therapeutics teams up with Boehringer Ingelheim in cancer studyMirati Therapeutics teams up with Boehringer Ingelheim in cancer study
seekingalpha.com - September 17 at 12:09 PM
Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective InhibitorBoehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor
finance.yahoo.com - September 17 at 12:09 PM
HC Wainwright Raises Mirati Therapeutics (NASDAQ:MRTX) Price Target to $185.00HC Wainwright Raises Mirati Therapeutics (NASDAQ:MRTX) Price Target to $185.00
americanbankingnews.com - September 17 at 11:06 AM
Mirati Therapeutics (NASDAQ:MRTX) Price Target Raised to $185.00 at HC WainwrightMirati Therapeutics (NASDAQ:MRTX) Price Target Raised to $185.00 at HC Wainwright
americanbankingnews.com - September 17 at 11:06 AM
Mirati Therapeutics (NASDAQ:MRTX) Sets New 1-Year High at $156.82Mirati Therapeutics (NASDAQ:MRTX) Sets New 1-Year High at $156.82
americanbankingnews.com - September 15 at 2:17 PM
Qorvo Announces Proposed $700 Million Senior Notes OfferingQorvo Announces Proposed $700 Million Senior Notes Offering
finance.yahoo.com - September 15 at 9:44 AM
Mirati Therapeutics (NASDAQ:MRTX) Trading 10.3% Higher Mirati Therapeutics (NASDAQ:MRTX) Trading 10.3% Higher
americanbankingnews.com - September 14 at 7:02 PM
The Launch of Nasdaq Junior BiotechThe Launch of Nasdaq Junior Biotech
nasdaq.com - September 3 at 2:12 PM
Mirati Therapeutics (NASDAQ:MRTX) Sets New 1-Year High at $153.39Mirati Therapeutics (NASDAQ:MRTX) Sets New 1-Year High at $153.39
americanbankingnews.com - August 31 at 6:48 AM
Mirati Therapeutics (NASDAQ:MRTX) Stock Rating Upgraded by BidaskClubMirati Therapeutics (NASDAQ:MRTX) Stock Rating Upgraded by BidaskClub
americanbankingnews.com - August 22 at 2:19 AM
MRTX Crosses Above Average Analyst TargetMRTX Crosses Above Average Analyst Target
nasdaq.com - August 18 at 12:53 PM
J.P. Morgan: 2 5G Stocks to Consider (And 1 to Avoid)J.P. Morgan: 2 5G Stocks to Consider (And 1 to Avoid)
finance.yahoo.com - August 12 at 11:17 AM
Mirati Therapeutics EPS beats by $0.20Mirati Therapeutics EPS beats by $0.20
seekingalpha.com - August 6 at 5:45 PM
How Does Mirati Therapeutics (NASDAQ:MRTX) CEO Salary Compare to Peers?How Does Mirati Therapeutics' (NASDAQ:MRTX) CEO Salary Compare to Peers?
finance.yahoo.com - August 4 at 2:42 PM
How Does Mirati Therapeutics' (NASDAQ:MRTX) CEO Salary Compare to Peers?How Does Mirati Therapeutics' (NASDAQ:MRTX) CEO Salary Compare to Peers?
finance.yahoo.com - August 4 at 2:42 PM
Qorvo® to Present at KeyBanc Capital Markets' Future of Technology Series Virtual ConferenceQorvo® to Present at KeyBanc Capital Markets' Future of Technology Series Virtual Conference
finance.yahoo.com - August 4 at 9:41 AM
5G Stocks To Buy And Watch: 5G Smartphones Sales Rise, Apple Still To Come5G Stocks To Buy And Watch: 5G Smartphones Sales Rise, Apple Still To Come
finance.yahoo.com - August 4 at 9:41 AM
Noteworthy Friday Option Activity: MRTX, MU, GRUBNoteworthy Friday Option Activity: MRTX, MU, GRUB
www.nasdaq.com - July 24 at 5:58 PM
Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th AMirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th A
www.bloomberg.com - July 9 at 5:41 PM
MRTX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Mirati Therapeutics, Inc. and Encourages Investors to Contact the FirmMRTX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Mirati Therapeutics, Inc. and Encourages Investors to Contact the Firm
finance.yahoo.com - July 6 at 6:27 PM
Interesting MRTX Put And Call Options For October 16thInteresting MRTX Put And Call Options For October 16th
www.nasdaq.com - June 9 at 1:22 PM
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare ConferenceMirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
www.prnewswire.com - June 5 at 9:44 AM
Here is What Hedge Funds Think About Qorvo Inc (QRVO)Here is What Hedge Funds Think About Qorvo Inc (QRVO)
finance.yahoo.com - June 1 at 12:22 PM
Mirati Therapeutics EPS misses by $0.34, misses on revenueMirati Therapeutics EPS misses by $0.34, misses on revenue
seekingalpha.com - May 7 at 6:34 PM
Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - April 27 at 1:41 PM
Mirati Dives As Short Seller Says Key Pipeline Assets DoomedMirati Dives As Short Seller Says Key Pipeline Assets Doomed
finance.yahoo.com - April 21 at 5:32 PM
How A Short-Seller's Damning Report Sent This Cancer Biotech TumblingHow A Short-Seller's Damning Report Sent This Cancer Biotech Tumbling
finance.yahoo.com - April 21 at 5:32 PM
Mirati Therapeutics down 6% as Kerrisdale shortsMirati Therapeutics down 6% as Kerrisdale shorts
seekingalpha.com - April 21 at 12:31 PM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Mirati Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Mirati Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 20 at 7:39 AM
Is Mirati Therapeutics, Inc. (MRTX) A Good Stock To Buy?Is Mirati Therapeutics, Inc. (MRTX) A Good Stock To Buy?
finance.yahoo.com - March 26 at 1:44 PM
The Prognosis For Mirati TherapeuticsThe Prognosis For Mirati Therapeutics
seekingalpha.com - February 28 at 1:34 PM
Mirati Therapeutics, Inc. Just Released Its Full-Year Earnings: Here's What Analysts ThinkMirati Therapeutics, Inc. Just Released Its Full-Year Earnings: Here's What Analysts Think
finance.yahoo.com - February 27 at 11:11 AM
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate UpdatesMirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates
finance.yahoo.com - February 25 at 8:26 AM
Mirati Therapeutics, Inc. Common Stock (MRTX) Option ChainMirati Therapeutics, Inc. Common Stock (MRTX) Option Chain
www.nasdaq.com - February 16 at 5:46 PM
Oversold Conditions For Mirati Therapeutics (MRTX)Oversold Conditions For Mirati Therapeutics (MRTX)
www.nasdaq.com - January 31 at 2:06 PM
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional SharesMirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
finance.yahoo.com - January 14 at 5:24 PM
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters Option To Purchase Additional SharesMirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
www.prnewswire.com - January 14 at 4:15 PM
Mirati Therapeutics prices stock offering at $97.50; shares down 2% premarketMirati Therapeutics prices stock offering at $97.50; shares down 2% premarket
seekingalpha.com - January 10 at 5:19 PM
Mirati Therapeutics Announces Pricing Of Public Offering Of Common StockMirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
finance.yahoo.com - January 9 at 10:16 PM
Mirati Therapeutics Announces Proposed Public Offering of Common StockMirati Therapeutics Announces Proposed Public Offering of Common Stock
www.prnewswire.com - January 8 at 4:11 PM
Mirati Therapeutics Announces Executive Management ChangesMirati Therapeutics Announces Executive Management Changes
finance.yahoo.com - January 6 at 5:25 PM
Heres Why Mirati Therapeutics Jumped 28% in DecemberHere's Why Mirati Therapeutics Jumped 28% in December
www.fool.com - January 4 at 8:35 PM
Here's What We Think About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO PayHere's What We Think About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay
finance.yahoo.com - January 3 at 1:55 PM
Mirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare ConferenceMirati Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference
www.prnewswire.com - January 2 at 4:52 PM
Commit To Purchase Mirati Therapeutics At $90, Earn 14.6% Using OptionsCommit To Purchase Mirati Therapeutics At $90, Earn 14.6% Using Options
www.nasdaq.com - December 30 at 4:07 PM
This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.